Evaluation of a New ¹⁷⁷Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5

Targeted radionuclide therapy of somatostatin receptor (SST)-expressing tumors is only partially addressed by the established somatostatin analogs having an affinity for the SST subtype 2 (SST2). Aiming to target a broader spectrum of tumors, we evaluated the bis-iodo-substituted somatostatin analog...

Description complète

Détails bibliographiques

Auteurs principaux:	Rosalba Mansi, Guillaume Pierre Nicolas, Luigi Del Pozzo, Karim Alexandre Abid, Eric Grouzmann, Melpomeni Fani
Format:	Artigo
Langue:	Inglês
Publié:	MDPI AG 2020-09-01
Collection:	Molecules
Sujets:	radiolabeled somatostatin analogs SST2 SST5 Lu-177 targeted radionuclide therapy neuroendocrine tumors
Accès en ligne:	https://www.mdpi.com/1420-3049/25/18/4155
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!